Ligand Pharmaceuticals Incorporated (LGND) SEC Filings & Earnings Calls

Royalty revenue depends on AvenCell's clinical and commercial success, which is uncertain.

“the possibility that conditions to future funding are not satisfied or that optional investments are not made; AvenCell’s ability to use the financing as anticipated and to continue funding its operations and development programs” · word for word

Royalty revenue dependent on Santen's commercialization success.

“Ligand will receive a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and Africa” · word for word

Concentration risk on key royalty products

“Filspari and Kyprolis together represent a significant portion of royalty revenue; any decline in partner sales could impact results.”

Integration risk from XOMA acquisition

“The XOMA Acquisition adds complexity and requires successful integration of over 100 additional royalty assets.”

Increased R&D expense due to funding arrangement with Orchestra BioMed; transaction costs from XOMA acquisition.

“Research and development expense was $14.7 million, compared with $6.6 million in the second quarter of 2025. The increase was primarily driven by the $12.3 million research and development funding arrangement with Orchestra BioMed.” · word for word

Integration risk from doubling portfolio size and managing >200 royalty assets.

“Ligand’s portfolio has more than doubled in size, now comprising over 200 commercial, clinical, and preclinical stage royalty assets.” · word for word

Contingent value rights tied to pending litigation outcomes may create uncertainty.

“one non-transferable Contingent Value Right per share entitling the holder to receive a portion of 75% of the net proceeds that may result from certain pending litigation at XOMA Royalty”

Dilution risk and potential cash outflow upon conversion.

“Conversion feature may dilute shareholders; company may settle in cash or stock.”

Increased debt capacity and potential dilution from convertible notes.

“Amendment allows for convertible notes issuance; adjusted EBITDA covenants.”

Transaction risks include failure to obtain stockholder approval, regulatory approvals, integration challenges, and litigation.

“Risks and uncertainties include... failure to obtain necessary regulatory approvals and failure to obtain XOMA Royalty stockholder approval... disruption from the transaction... risk of litigation.”

Viking TR-Beta program termination dispute

“Viking is disputing our right to terminate the TR-Beta Program pursuant to the terms of the License Agreement. We believe our right to terminate the TR-Beta Program is valid pursuant to the terms of the License Agreement, and we intend to vigorously enforce our right to terminate the TR-Beta Program under the License Agreement.” · word for word

Captisol revenue volatility

“Captisol sales decreased by $4.8 million, or 36%, to $8.7 million in Q1 2026 compared to $13.5 million in Q1 2025, primarily due to the timing of customer orders.” · word for word

Fair value volatility from equity investments

“The loss from change in fair value of equity-method investments and other investments was $49.2 million in Q1 2026, attributable to the fair value changes of the shares of Pelthos common stock and Pelthos Series A convertible preferred stock that we acquired in connection with the Pelthos Transaction in July 2025.” · word for word

Captisol sales decline on order timing; potential volatility.

“Captisol sales $8.7M vs $13.5M YoY (-36%).”

XOMA acquisition integration risk; pending stockholder approval.

“Transaction subject to customary closing conditions, including XOMA stockholder approval.”

Non-cash loss from Pelthos investment fair value change.

“$49.2M non-cash loss from changes in fair value of equity-method investment in Pelthos.”

Merger completion risk

“The consummation of the Merger is subject to the satisfaction or waiver of customary conditions as set forth in the Merger Agreement, including (i) adoption and approval of the Merger Agreement by the holders of at least a majority of the combined voting power of the outstanding shares of Common Stock” · word for word

Viking disputes the termination, leading to potential litigation and uncertainty over the program's future.

“Viking is disputing the Company's right to terminate the TR-Beta Program... The Company believes its right to terminate... is valid... and intends to vigorously enforce its right.”

Transaction subject to stockholder and regulatory approvals.

“Conditions include XOMA Royalty stockholder approval and HSR waiting period.”

Generic competition for Evomela

“Teva will be permitted to market a generic version of Evomela in the United States starting on June 1, 2026.” · word for word

Generic competition for Kyprolis

“It was publicly reported that the U.S. launch date for at least Breckenridge Pharmaceuticals’ applicable generic product will be 'on a date that is held as confidential in 2027 or sooner, depending on certain occurrences.'” · word for word

Captisol supply chain risk

“We obtain Captisol from Hovione, our third-party manufacturer, primarily at their facilities in Ireland and Portugal. If Hovione were to cease to be able, for any reason, to supply Captisol to us in the amounts we require, or decline to supply Captisol to us, we would be required to seek an alternative source.” · word for word

Partner concentration risk

“A significant portion of our royalty revenue is based on sales of Kyprolis by Amgen, sales of Qarziba by Recordati, sales of Filspari by Travere, sales of Evomela by Acrotech Biopharma, sales of Teriparatide by Alvogen/Adalvo, sales of Vaxneuvance and Capvaxive by Merck, sales of Ohtuvayre by Verona Pharma, now a subsidiary of Merck, and sales of Rylaze by J” · word for word

Financial royalty asset impairment related to Agenus returned partner programs

“Financial royalty asset impairment was $6.2 million for the fourth quarter of 2025 related to Agenus returned partner programs, compared to $4.1 million for the same period in 2024 related to the discontinuation of Takeda’s soticlestat program.” · word for word

Investment risk in Athira Pharma, a biotech company with potential clinical and regulatory uncertainties.

“Private placement investment in Athira Pharma, Inc. without disclosed terms or performance metrics.”

Concentration risk on key partnered drugs

“Royalties increased by $14.9 million, or 47%, to $46.6 million in Q3 2025 compared to $31.7 million in Q3 2024, primarily due to increase in Filspari, Ohtuvayre and Capvaxive sales.” · word for word

Convertible note dilution risk

“On August 14, 2025, we completed the offering of 0.75% convertible senior notes due 2030. The aggregate principal amount of the notes sold was $460 million.” · word for word

Fair value volatility from equity investments

“The gain (loss) from change in fair value of equity-method investments and other investments increased by $78.9 million to $75.9 million in Q3 2025, primarily attributable to the fair value changes of the Pelthos common shares and Pelthos Series A preferred shares.” · word for word

Revenue growth partly from one-time gains; R&D expenses increased due to royalty financing agreements.

“Revenue includes $24.5M Zelsuvmi out-license and $28.6M Pelthos gain; R&D expenses increased due to $17.8M one-time charge.”